LOGIN  |  REGISTER
Assertio
Amneal Pharmaceuticals

Emergent BioSolutions to Participate in Upcoming Investor Conferences

May 14, 2025 | Last Trade: US$8.79 0.12 -1.35

GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of its executive management team will participate in the following investor conferences:

  • RBC Global Healthcare Conference (New York, New York)
    Fireside chat on Tuesday, May 20 at 3:35 pm ET
    Virtual attendees can participate via webcast
  • Goldman Sachs Leveraged Finance Conference, May 29, 2025 (Dana Point, California)
  • Benchmark’s 5th Annual Healthcare House Call Virtual Investor Conference
    Presentation on Thursday, May 29
  • Jefferies Global Healthcare Conference (New York, New York)
    Presentation on Thursday, June 5 at 1:25 pm ET
    Virtual attendees can participate via webcast

A replay of the presentations can be accessed from the Investors page of Emergent’s website.

About Emergent BioSolutions 

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedInXInstagramApple Podcasts and Spotify. 

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Assal Hellmer
Vice President, Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.

Recursion

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page